Reuters logo
BRIEF-Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA
2017年10月2日 / 晚上8点37分 / 16 天前

BRIEF-Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA

Oct 2 (Reuters) - Vical Inc

* Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA based on a single phase 2 efficacy trial

* Vical Inc - ‍plans to initiate phase 2 trial of VL-2397 for treatment of invasive Aspergillosis in 4Q 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below